211 related articles for article (PubMed ID: 38075241)
21. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape.
Xie D; Jin X; Sun R; Zhang M; Lu W; Cao X; Guo R; Zhang Y; Zhao M
Transl Oncol; 2023 Aug; 34():101695. PubMed ID: 37224766
[TBL] [Abstract][Full Text] [Related]
22. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
23. Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity.
Zoine JT; Immadisetty K; Ibanez-Vega J; Moore SE; Nevitt C; Thanekar U; Tian L; Karouni A; Chockley PJ; Arthur B; Sheppard H; Klco JM; Langfitt DM; Krenciute G; Gottschalk S; Babu MM; Velasquez MP
Cell Rep Med; 2024 Feb; 5(2):101422. PubMed ID: 38350450
[TBL] [Abstract][Full Text] [Related]
24. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
El Khawanky N; Hughes A; Yu W; Myburgh R; Matschulla T; Taromi S; Aumann K; Clarson J; Vinnakota JM; Shoumariyeh K; Miething C; Lopez AF; Brown MP; Duyster J; Hein L; Manz MG; Hughes TP; White DL; Yong ASM; Zeiser R
Nat Commun; 2021 Nov; 12(1):6436. PubMed ID: 34750374
[TBL] [Abstract][Full Text] [Related]
25. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
26. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
Kubicka E; Lum LG; Huang M; Thakur A
Front Immunol; 2022; 13():899468. PubMed ID: 36389764
[TBL] [Abstract][Full Text] [Related]
28. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
29. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing.
Riberdy JM; Zhou S; Zheng F; Kim YI; Moore J; Vaidya A; Throm RE; Sykes A; Sahr N; Bonifant CL; Ryu B; Gottschalk S; Velasquez MP
Mol Ther Methods Clin Dev; 2020 Sep; 18():571-581. PubMed ID: 32775492
[TBL] [Abstract][Full Text] [Related]
30. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
[TBL] [Abstract][Full Text] [Related]
31. Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy.
Kittel-Boselli E; Soto KEG; Loureiro LR; Hoffmann A; Bergmann R; Arndt C; Koristka S; Mitwasi N; Kegler A; Bartsch T; Berndt N; Altmann H; Fasslrinner F; Bornhäuser M; Bachmann MP; Feldmann A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638268
[TBL] [Abstract][Full Text] [Related]
32. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
Mu-Mosley H; Ostermann L; Muftuoglu M; Vaidya A; Bonifant CL; Velasquez MP; Gottschalk S; Andreeff M
Front Immunol; 2022; 13():880108. PubMed ID: 35615350
[TBL] [Abstract][Full Text] [Related]
33. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
34. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.
Guijarro-Albaladejo B; Marrero-Cepeda C; Rodríguez-Arbolí E; Sierro-Martínez B; Pérez-Simón JA; García-Guerrero E
Front Cell Dev Biol; 2024; 12():1376554. PubMed ID: 38694825
[TBL] [Abstract][Full Text] [Related]
36. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
37. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
38. IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
Perriello VM; Rotiroti MC; Pisani I; Galimberti S; Alberti G; Pianigiani G; Ciaurro V; Marra A; Sabino M; Tini V; Spinozzi G; Mezzasoma F; Morena F; Martino S; Salerno D; Ashby JF; Wingham B; Serafini M; Martelli MP; Falini B; Biondi A; Tettamanti S
Blood Adv; 2023 Jun; 7(12):2855-2871. PubMed ID: 36521101
[TBL] [Abstract][Full Text] [Related]
39. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.
Kim MY; Yu KR; Kenderian SS; Ruella M; Chen S; Shin TH; Aljanahi AA; Schreeder D; Klichinsky M; Shestova O; Kozlowski MS; Cummins KD; Shan X; Shestov M; Bagg A; Morrissette JJD; Sekhri P; Lazzarotto CR; Calvo KR; Kuhns DB; Donahue RE; Behbehani GK; Tsai SQ; Dunbar CE; Gill S
Cell; 2018 May; 173(6):1439-1453.e19. PubMed ID: 29856956
[TBL] [Abstract][Full Text] [Related]
40. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
